DIHEXA
Monograph · DSix-amino acid HGF (hepatocyte growth factor) mimetic. Crosses BBB orally; promotes synaptogenesis in animal models.
How it clearsHalf cleared in ~8h. Most (~96%) gone by ~2d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
Washington State University (Harding lab) candidate. Preclinical models show ~7-orders-of-magnitude greater potency than BDNF for synaptogenesis. Patented; M3 Biotechnology / Athira Pharma developed related candidates. No published human trials of DIHEXA itself.
Speculative cognitive theory — no strong human trial data yet. The mechanistic logic is coherent, but effect sizes and responder rates in humans are unknown. Log onset timing, dose, and task performance specifically — not general feeling.
No human safety data. Strong synaptogenic effect in rodents could plausibly drive un-modeled CNS adverse effects in humans. Identity verification poor.
norLeu-Tyr-Ile-(6)-amido-hexanoic acid. Modified scaffold.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyStack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Harding lab developed Dihexa as an angiotensin-IV-derivative analog for cognitive disorders. Pre-clinical data shows synaptogenic activity ~7 orders of magnitude greater than BDNF in vitro. The lab has published primarily on rodent models; human clinical trials are absent.
No human Phase 2/3 trials registered. The synaptogenic-magnitude claim is from in-vitro data and has not been translated to clinical outcomes. PCAC review scheduled February 2027 — until then, Dihexa is research-grey only.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA Cat. 2 removed Apr 2026 — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.
Pre-filled with this compound's published dose range: 8-45 mg · daily, oral
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 1-8 mg/day oral (angiotensin IV analog, blood-brain barrier crossing)
Research-grey only. Higher per-mg cost than typical research peptides because oral bioavailability allows higher dosing. Human data essentially absent — all efficacy reads from rodent models. On the Feb 2027 PCAC docket.
As of 2026-04No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.